TG Therapeutics Details Planned BRIUMVI Presentations for CMSC 2026

Key Takeaways

• TG Therapeutics presented new data on BRIUMVI (ublituximab-xiiy) at the American Academy of Neurology (AAN) 2026 annual meeting focused on relapsing multiple sclerosis (RMS).
• The presentations included findings from the ENABLE Phase 4 observational study and updated safety data from the ENHANCE dosing study.
• The company’s latest research reflects an ongoing effort to expand real-world and administration-related evidence for BRIUMVI in a competitive anti-CD20 treatment market.

TG Therapeutics announced the presentation of new BRIUMVI data at the American Academy of Neurology 2026 annual meeting in Chicago, highlighting ongoing research into the therapy’s use in relapsing forms of multiple sclerosis (RMS). The company’s presentations focused on real-world clinical experience and dosing strategies for the anti-CD20 monoclonal antibody, which was approved in the United States in 2022 for adults with RMS.

One of the featured presentations examined findings from ENABLE, described by TG Therapeutics as the first Phase 4 observational study evaluating patients with RMS initiating ublituximab therapy in routine clinical practice. The study is designed to assess how the drug performs outside the controlled setting of pivotal clinical trials, including measures related to treatment experience and tolerability. Lead investigator Carrie Hersh, DO, of the Cleveland Clinic Lou Ruvo Center for Brain Health, presented the data during the meeting’s multiple sclerosis clinical trials session.

A second presentation provided updated results from the ENHANCE study, which is evaluating the safety and tolerability of a modified ublituximab dosing regimen. The presentation was led by Barry A. Singer, MD, of the MS Center for Innovations in Care at Missouri Baptist Medical Center. TG Therapeutics has positioned the study as part of its effort to explore administration approaches that may improve infusion experience and operational flexibility.

BRIUMVI targets CD20-expressing B cells, a mechanism shared by several established therapies used in multiple sclerosis. According to the company, the antibody was glycoengineered to enhance B-cell depletion efficiency at lower doses. The drug is approved for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

The presentations come as TG Therapeutics continues expanding its evidence base for BRIUMVI through post-marketing and administration-focused studies. While the company characterized the findings as supportive of the therapy’s safety and real-world use, the conference presentations were not designed as head-to-head comparative trials against competing anti-CD20 agents. Additional data from ongoing studies, including investigations into subcutaneous formulations of BRIUMVI, are expected in the coming years.